Patricia Del Carmen Muñoz-Villegas (Patricia Muñoz-Villegas)

ORCID

Publication Activity (10 Years)

Years Active: 2018-2024
Publications (10 Years): 15

Top Venues

Clinical ophthalmology (Auckland, N.Z.)

Ophthalmology and therapy

Therapeutics and clinical risk management

Current eye research

Laboratorios Sophia

Universidad de Guadalajara Centro Universitario de Ciencias Biologicas y Agropecuarias (PHD)

This page only lists publications with an associated author ORCID identifier.

Affiliation History

Laboratorios Sophia Sep 01 2017

Mexico

Head of Biostatistics :: Medical Affairs

CEDE Jalisco Jan 01 2013 - Jul 14 2018

Mexico

Professor :: Forensic Science

Centro de Enseñanza Técnica Industrial Jan 25 2017 - Aug 31 2017

Mexico

Professor :: Tecnólogo Químico en Fármacos

University of Barcelona Oct 01 2014 - Oct 31 2016

Spain

Postdoctoral position :: Farmacología & Química Terapéutica

Colegio Libre De Estudios Universitarios Sep 01 2012 - Sep 30 2014

Mexico

Professor :: Forensic science

Centro Universitario UTEG Aug 01 2010 - Feb 28 2011

Mexico

Professor :: Exact and Natural Sciences

Education History

Universidad de Guadalajara Centro Universitario de Ciencias Biologicas y Agropecuarias Feb 01 2011 - Jan 31 2014

Mexico

PHD :: Ciencias Básicas

Publications

Patricia Del Carmen Muñoz-Villegas, Gisela García-Sánchez, Ricardo O Jauregui-Franco, Sebastian Quirarte-Justo, Alejandra Sánchez-Ríos, Oscar Olvera-Montaño
Influence of Environmental Factors with Clinical Signs and Symptoms in the Management of Dry Eye Disease. Clinical ophthalmology (Auckland, N.Z.) 18 (2024)
José M Torres-Arellano, Andrea Tornero-Jimenez, Alejandra Sánchez-Ríos, Oscar Olvera-Montaño, Patricia Del Carmen Muñoz-Villegas
Evaluation of the Relationship Between Diabetic Macular Edema and Renal Function in a Latino Population. Ophthalmology and therapy (2023)
Patricia Del Carmen Muñoz-Villegas, Alejandra Sánchez-Ríos, Oscar Olvera-Montaño
The Effect of Sodium Hyaluronate Eye Drops 2, 4 or 6 Times a Day on Signs and Symptoms of Dry Eye Disease. Clinical ophthalmology (Auckland, N.Z.) 17 (2023)
Leopoldo M Baiza-Durán, Patricia Del Carmen Muñoz-Villegas, Alejandra Sánchez-Ríos, Oscar Olvera-Montaño
Efficacy and Safety of an Ophthalmic DMPC-Based Nanoemulsion in Patients with Dry Eye Disease: A Phase I/II Randomized Clinical Trial. Journal of ophthalmology 2023 (2023)
Patricia Del Carmen Muñoz-Villegas, Humberto Martínez-Bautista, Oscar Olvera-Montaño
Determinants of adherence to treatment in patients with ophthalmic conditions. Expert review of clinical pharmacology (2023)
Claudia Palacio Pastrana, Patricia Del Carmen Muñoz-Villegas, Fernando Dániel-Dorantes, Alejandra Sánchez-Ríos, Oscar Olvera-Montaño, Yareni I Martínez-Montoya, Juan D Quintana-Hau, Leopoldo M Baiza-Durán
Evaluation of the Rheological Properties, Preclinical Safety, and Clinical Effectiveness of a New Dispersive Ophthalmic Viscoelastic Device for Cataract Surgery. Medical devices (Auckland, N.Z.) 15 (2022)
Alejandra Sánchez-Ríos, Elba Yadira Correa-Gallegos, José Manuel Medina-Espinoza, Andrea Anaid Navarro-Sanchez, Oscar Olvera-Montaño, Leopoldo Baiza-Durán, Patricia Del Carmen Muñoz-Villegas
Validation of a preclinical dry eye model in New Zealand white rabbits during and following topical instillation of 1% ophthalmic atropine sulfate. Animal models and experimental medicine 5 (3) (2022)
Patricia Del Carmen Muñoz-Villegas, Alejandra Sanchez-Rios, Mayra G Quinonez-Alvarado, Oscar Olvera-Montaño, Juan D Quintana-Hau, Leopoldo Baiza-Duran
Pharmacokinetics and Safety of an Intravitreal Humanized Anti-VEGF-A Monoclonal Antibody (PRO-169), a Biosimilar Candidate to Bevacizumab. Journal of experimental pharmacology 13 (2021)
Patricia Del Carmen Muñoz-Villegas, Andrea A Navarro-Sánchez, Alejandra Sánchez-Ríos, Oscar Olvera-Montaño, Leopoldo M Baiza-Durán
Reexamining Ophthalmic Drugs, Safety and Tolerability in Phase 1 Clinical Trials. Therapeutics and clinical risk management 17 (2021)
Sandra Belalcázar-Rey, Valeria Sánchez Huerta, Juan C Ochoa-Tabares, Samuel Altamirano Vallejo, Abraham Soto-Gómez, Rubén Suárez-Velasco, Filiberto García-Félix, Leopoldo Baiza-Durán, Oscar Olvera-Montaño, Patricia Del Carmen Muñoz-Villegas
Efficacy and Safety of Sodium Hyaluronate/chondroitin Sulfate Preservative-free Ophthalmic Solution in the Treatment of Dry Eye: A Clinical Trial. Current eye research 46 (7) (2020)
Claudia Palacio Pastrana, Eduardo Chávez-Mondragón, Abraham Soto-Gómez, Rubén Suárez-Velasco, Miguel Montes-Salcedo, Lourdes Fernández de Ortega, Linda Nasser-Nasser, Leopoldo Baiza-Durán, Oscar Olvera-Montaño, Patricia Del Carmen Muñoz-Villegas
Difluprednate 0.05% versus Prednisolone Acetate Post-Phacoemulsification for Inflammation and Pain: An Efficacy and Safety Clinical Trial. Clinical ophthalmology (Auckland, N.Z.) 14 (2020)
Leopoldo Baiza-Durán, Alejandra Sánchez-Ríos, Joel González-Barón, Oscar Olvera-Montaño, Elba Correa-Gallegos, Andrea Navarro-Sánchez, Patricia Del Carmen Muñoz-Villegas
Safety and tolerability evaluation after repeated intravitreal injections of a humanized anti-VEGF-A monoclonal antibody (PRO-169) versus ranibizumab in New Zealand white rabbits. International journal of retina and vitreous 6 (2020)
Oscar Olvera-Montaño, Leopoldo Baiza-Duran, Juan D Quintana-Hau, Mayra G Quiñonez-Alvarado, Wen Zeng, Li Gong, Patricia Del Carmen Muñoz-Villegas
Comparing The Efficacy Of An Anti-Human VEGF-A Neutralizing Antibody Versus Bevacizumab On A Laser-Induced Choroidal Neovascularization (CNV) Rhesus Monkey Model. Drug design, development and therapy 13 (2019)
Eduardo Chávez-Mondragón, Claudia Palacio, Abraham Soto-Gómez, Miguel Villanueva-Nájera, Guillermo De Wit-Carter, Ruben Suárez-Velasco, Leopoldo Baiza-Duran, Oscar Olvera-Montaño, Patricia Del Carmen Muñoz-Villegas
Efficacy and safety of bromfenac 0.09% and sodium hyaluronate 0.4% combination therapy, versus placebo in patients with pterygium I-III for clinical signs on ocular inflammation. Clinical ophthalmology (Auckland, N.Z.) 13 (2019)
Francisco Gómez-Aguayo, José A Paczka, Rubén Leñero-Córdova, Jesús Jiménez-Román, Jaime Davila-Villarreal, Curt Hartleben, Leopoldo Baiza-Durán, Oscar Olvera-Montaño, Francisco García-Velez, Patricia Del Carmen Muñoz-Villegas
A Phase III Randomized Clinical Trial of a 0.5% Timolol + 0.2% Brimonidine + 2.0% Dorzolamide Fixed Combination, Preservative-Free Ophthalmic Solution vs. 0.5% Timolol + 0.2% Brimonidine + 2.0% Dorzolamide Fixed Combination in Patients with Controlled Primary Open-Angle Glaucoma. Ophthalmology and therapy 7 (1) (2018)

Patricia Del Carmen Muñoz-Villegas.css-eqlu8i{font-size:small;padding-left:4px;} (Patricia Muñoz-Villegas)

Publication Activity (10 Years)

Top Topics

Top Venues

Patricia Del Carmen Muñoz-Villegas (Patricia Muñoz-Villegas)